Acrivon Therapeutics Inc (ACRV)

$2.00 -0.04 (-1.96%)
Market Cap 87.42M
Revenue (ttm) 0.00
Net Income (ttm) -77.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 461,500
Avg Vol 391,188
Day's Range N/A - N/A
Shares Out 42.85M
Stochastic %K 20%
Beta 1.92
Analysts Strong Sell
Price Target $11.50

Company Profile

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
nmarrone2207
nmarrone2207 Sep. 12 at 12:07 PM
$ACRV quick drop to 1.88 monday then we start back
0 · Reply
Dani_G_German
Dani_G_German Sep. 11 at 3:58 PM
$ACRV
0 · Reply
Bullbarbise
Bullbarbise Sep. 10 at 1:56 PM
$ACRV Ceo, has just to do one thing. Buy stocks and show to market that is the first doing this and trusting in what he is doing. It is a shame that ACRV it is not able to mantein 2 dollars value. More than a shame for a stock where analysts are having from 8 to 19 dollars target prices. Cases are 2: 1) Analysts are all people that it is better they go to fish. 2) This is pure speculation and stock holders are thinking to play just betweekn 1.4 to 2.19. And this is the most sad scenario.
1 · Reply
vcn_PL
vcn_PL Sep. 9 at 1:10 PM
$ACRV CEO tightened the only thing that matters — ACR-368 all-comer interim mid-Nov, ~45 pts. Bar he’s selling is ~30% + 5.5–6 mo DOR vs 13% SOC. Prefers mono Arm 4 for AA if it holds. 2316 still in expansion, CDK11 IND early ’27. Platform talk, no durability update. Tape shouldn’t re-rate on a fireside. November is the event.
0 · Reply
Bullbarbise
Bullbarbise Sep. 8 at 10:39 AM
$ACRV
0 · Reply
Trinity031983
Trinity031983 Sep. 3 at 9:52 PM
$ACRV
0 · Reply
Trinity031983
Trinity031983 Sep. 3 at 9:50 PM
$ACRV
1 · Reply
Bullbarbise
Bullbarbise Sep. 3 at 3:22 PM
$ACRV
0 · Reply
Dani_G_German
Dani_G_German Sep. 3 at 3:15 PM
$ACRV This is probably the longest time we stayed advic above 2. Something is definitely brewing
0 · Reply
nmarrone2207
nmarrone2207 Sep. 2 at 10:35 PM
$ACRV friday we see big green candle with golden cross!
1 · Reply
Latest News on ACRV
Acrivon Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 8:35 AM EDT - 4 days ago

Acrivon Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Acrivon Therapeutics Slides: Corporate presentation

Sep 7, 2026, 7:00 AM EDT - 6 days ago

Acrivon Therapeutics Slides: Corporate presentation

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Sep 2, 2026, 8:00 AM EDT - 11 days ago

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Aug 31, 2026, 8:30 AM EDT - 13 days ago

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Acrivon Therapeutics reports Q2 EPS (43c), consensus (50c)

2026-08-17T08:44:37.000Z - 27 days ago

Acrivon Therapeutics reports Q2 EPS (43c), consensus (50c)

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Aug 12, 2026, 4:05 PM EDT - 4 weeks ago

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Acrivon Therapeutics Quarterly report: Q2 2026

Acrivon Therapeutics Earnings release: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Acrivon Therapeutics Earnings release: Q2 2026

Acrivon Therapeutics Slides: Corporate presentation

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Acrivon Therapeutics Slides: Corporate presentation

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Aug 5, 2026, 8:30 AM EDT - 5 weeks ago

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Jul 21, 2026, 4:30 PM EDT - 7 weeks ago

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Acrivon Therapeutics assumed with an Outperform at Oppenheimer

2026-06-15T11:43:03.000Z - 3 months ago

Acrivon Therapeutics assumed with an Outperform at Oppenheimer

Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 9:00 AM EDT - 3 months ago

Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Acrivon Therapeutics Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 3 months ago

Acrivon Therapeutics Proxy statement: Proxy filing

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

May 21, 2026, 7:30 AM EDT - 3 months ago

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 4:00 PM EDT - 4 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)

2026-05-13T21:27:56.000Z - 4 months ago

Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

May 13, 2026, 4:10 PM EDT - 4 months ago

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Acrivon Therapeutics Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 4 months ago

Acrivon Therapeutics Earnings release: Q1 2026

Acrivon Therapeutics Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 4 months ago

Acrivon Therapeutics Quarterly report: Q1 2026

Acrivon Therapeutics Slides: Corporate presentation

May 13, 2026, 4:00 PM EDT - 4 months ago

Acrivon Therapeutics Slides: Corporate presentation

Acrivon Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Acrivon Therapeutics Proxy statement: Proxy filing

Acrivon Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Acrivon Therapeutics Proxy statement: Proxy filing

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Apr 17, 2026, 4:00 PM EDT - 4 months ago

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)

2026-03-19T11:25:53.000Z - 5 months ago

Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)

Acrivon Therapeutics sees cash runway into 2Q27

2026-03-19T11:25:40.000Z - 5 months ago

Acrivon Therapeutics sees cash runway into 2Q27

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 19, 2026, 7:21 AM EDT - 5 months ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Acrivon Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Acrivon Therapeutics Earnings release: Q4 2025

Acrivon Therapeutics Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Acrivon Therapeutics Annual report: Q4 2025

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Mar 17, 2026, 5:54 PM EDT - 5 months ago

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 6 months ago

Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Acrivon Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 6 months ago

Acrivon Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026

Feb 27, 2026, 8:00 AM EST - 6 months ago

Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026

Acrivon Therapeutics Slides: FY 2026

Feb 27, 2026, 8:00 AM EST - 6 months ago

Acrivon Therapeutics Slides: FY 2026

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 6 months ago

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Feb 23, 2026, 8:00 AM EST - 6 months ago

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Acrivon Therapeutics announces completion, certification of CLIA certified lab

2026-02-18T13:11:04.000Z - 6 months ago

Acrivon Therapeutics announces completion, certification of CLIA certified lab

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Feb 18, 2026, 8:00 AM EST - 6 months ago

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Jan 23, 2026, 8:11 AM EST - 7 months ago

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler

2026-01-09T11:46:33.000Z - 8 months ago

Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results

2026-01-08T14:04:25.000Z - 8 months ago

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results

Acrivon Therapeutics Transcript: Study Update

Jan 8, 2026, 8:30 AM EST - 8 months ago

Acrivon Therapeutics Transcript: Study Update

Acrivon Therapeutics Press release: Study Update

Jan 8, 2026, 8:30 AM EST - 8 months ago

Acrivon Therapeutics Press release: Study Update

Acrivon Therapeutics Slides: Study Update

Jan 8, 2026, 8:30 AM EST - 8 months ago

Acrivon Therapeutics Slides: Study Update

Acrivon Therapeutics announces progress across pipeline

2026-01-08T12:35:54.000Z - 8 months ago

Acrivon Therapeutics announces progress across pipeline

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Jan 8, 2026, 7:30 AM EST - 8 months ago

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies

2026-01-06T12:41:29.000Z - 8 months ago

Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Jan 6, 2026, 7:30 AM EST - 8 months ago

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Dec 17, 2025, 9:34 AM EST - 8 months ago

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Acrivon to provide ACR-368, ACR-2316 clinical data in January

2025-12-17T12:36:13.000Z - 9 months ago

Acrivon to provide ACR-368, ACR-2316 clinical data in January

Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)

2025-11-13T21:50:27.000Z - 10 months ago

Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 13, 2025, 4:10 PM EST - 10 months ago

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Acrivon Therapeutics Earnings release: Q3 2025

Acrivon Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Acrivon Therapeutics Quarterly report: Q3 2025

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 22, 2025, 4:15 PM EDT - 10 months ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer

2025-08-14T10:30:20.000Z - 1 year ago

Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer

Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)

2025-08-13T20:45:13.000Z - 1 year ago

Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 13, 2025, 4:15 PM EDT - 1 year ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Quarterly report: Q2 2025

Acrivon Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q2 2025

Acrivon Therapeutics Slides: Corporate Presentation

Jun 13, 2025, 10:00 AM EDT - 1 year ago

Acrivon Therapeutics Slides: Corporate Presentation

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

2025-05-16T16:30:10.000Z - 1 year ago

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Acrivon Therapeutics Quarterly report: Q1 2025

Acrivon Therapeutics Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q1 2025

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 5:44 PM EDT - 1 year ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q4 2024

Acrivon Therapeutics Annual report: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Acrivon Therapeutics Annual report: Q4 2024

Acrivon Therapeutics Transcript: Status Update

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Transcript: Status Update

Acrivon Therapeutics Slides: Status Update

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Slides: Status Update

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acrivon Therapeutics Quarterly report: Q3 2024

Acrivon Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acrivon Therapeutics Earnings release: Q3 2024

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Acrivon Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 8:35 AM EDT - 1 year ago

Acrivon Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Acrivon Therapeutics Transcript: Study Update

Sep 14, 2024, 9:00 AM EDT - 1 year ago

Acrivon Therapeutics Transcript: Study Update

Acrivon Therapeutics Press release: Study Update

Sep 14, 2024, 9:00 AM EDT - 1 year ago

Acrivon Therapeutics Press release: Study Update

Acrivon Therapeutics Slides: Study Update

Sep 14, 2024, 9:00 AM EDT - 1 year ago

Acrivon Therapeutics Slides: Study Update

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Quarterly report: Q2 2024

Acrivon Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q2 2024

Acrivon Therapeutics Slides: Corporate Presentation

Jun 4, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Slides: Corporate Presentation

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Quarterly report: Q1 2024

Acrivon Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q1 2024

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 7:16 PM EDT - 2 years ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Acrivon Therapeutics Transcript: R&D Update

Apr 24, 2024, 4:15 PM EDT - 2 years ago

Acrivon Therapeutics Transcript: R&D Update

Acrivon Therapeutics Slides: R&D Update

Apr 24, 2024, 4:15 PM EDT - 2 years ago

Acrivon Therapeutics Slides: R&D Update

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 24, 2024, 4:01 PM EDT - 2 years ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Acrivon Therapeutics Registration statement: Registration Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Registration statement: Registration Filing

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 16, 2024, 8:01 PM EDT - 2 years ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 9, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Acrivon Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Annual report: Q4 2023

Acrivon Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q4 2023

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Mar 5, 2024, 4:30 PM EST - 2 years ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Registration statement: Registration Filing

Dec 1, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Registration statement: Registration Filing

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Quarterly report: Q3 2023

Acrivon Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Earnings release: Q3 2023

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Sep 5, 2023, 4:05 PM EDT - 3 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 30, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Quarterly report: Q2 2023

Acrivon Therapeutics Earnings release: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q2 2023

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 22, 2023, 4:00 PM EDT - 3 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Acrivon Therapeutics Proxy statement: Proxy Filing

May 30, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

nmarrone2207
nmarrone2207 Sep. 12 at 12:07 PM
$ACRV quick drop to 1.88 monday then we start back
0 · Reply
Dani_G_German
Dani_G_German Sep. 11 at 3:58 PM
$ACRV
0 · Reply
Bullbarbise
Bullbarbise Sep. 10 at 1:56 PM
$ACRV Ceo, has just to do one thing. Buy stocks and show to market that is the first doing this and trusting in what he is doing. It is a shame that ACRV it is not able to mantein 2 dollars value. More than a shame for a stock where analysts are having from 8 to 19 dollars target prices. Cases are 2: 1) Analysts are all people that it is better they go to fish. 2) This is pure speculation and stock holders are thinking to play just betweekn 1.4 to 2.19. And this is the most sad scenario.
1 · Reply
vcn_PL
vcn_PL Sep. 9 at 1:10 PM
$ACRV CEO tightened the only thing that matters — ACR-368 all-comer interim mid-Nov, ~45 pts. Bar he’s selling is ~30% + 5.5–6 mo DOR vs 13% SOC. Prefers mono Arm 4 for AA if it holds. 2316 still in expansion, CDK11 IND early ’27. Platform talk, no durability update. Tape shouldn’t re-rate on a fireside. November is the event.
0 · Reply
Bullbarbise
Bullbarbise Sep. 8 at 10:39 AM
$ACRV
0 · Reply
Trinity031983
Trinity031983 Sep. 3 at 9:52 PM
$ACRV
0 · Reply
Trinity031983
Trinity031983 Sep. 3 at 9:50 PM
$ACRV
1 · Reply
Bullbarbise
Bullbarbise Sep. 3 at 3:22 PM
$ACRV
0 · Reply
Dani_G_German
Dani_G_German Sep. 3 at 3:15 PM
$ACRV This is probably the longest time we stayed advic above 2. Something is definitely brewing
0 · Reply
nmarrone2207
nmarrone2207 Sep. 2 at 10:35 PM
$ACRV friday we see big green candle with golden cross!
1 · Reply
Dani_G_German
Dani_G_German Sep. 2 at 6:56 PM
$ACRV
0 · Reply
Lanikai16
Lanikai16 Sep. 2 at 1:09 PM
$ACRV Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, September 9, 2026, at 8:35 a.m. ET at the 2026 Cantor Global Healthcare Conference in New York, NY.
0 · Reply
Bullbarbise
Bullbarbise Sep. 1 at 2:45 PM
$ACRV Strange cases of the life. Michaela Levin got incentive stocks at close prise 2.09. And part of that will be ready for sell in one month. Exactly before an important Cancer congress. It is not letting understand people what is happening here? What is strange is why people is not buiyng huge amount of stocks. Here very soon will change totally the price. Very very very soon.....
1 · Reply
Bullbarbise
Bullbarbise Aug. 31 at 5:17 PM
$ACRV Michaela Levin on board. Go to see who she is and what she is capable to do. Very competent and effective Chief Business Officer. Look at all Pharma she worked in it. People has to connect things togheter and understand what is happening here.
0 · Reply
PreGigs
PreGigs Aug. 31 at 3:48 PM
$ACRV Might add some more here
0 · Reply
Bullbarbise
Bullbarbise Aug. 31 at 3:32 PM
$ACRV ...day by day closer to ACR368 data... Comin bulls...
0 · Reply
Dani_G_German
Dani_G_German Aug. 28 at 9:25 PM
$ACRV stayed above 2 all week, that’s a good sign
0 · Reply
Bullbarbise
Bullbarbise Aug. 27 at 12:33 PM
$ACRV
0 · Reply
Dani_G_German
Dani_G_German Aug. 26 at 3:16 PM
$ACRV I guess not. Ugh
0 · Reply
Bullbarbise
Bullbarbise Aug. 26 at 2:04 PM
$ACRV it goes down? I'll buy more. No problems... Thanks a lot for this opportunity
0 · Reply
Bullbarbise
Bullbarbise Aug. 25 at 12:34 PM
$ACRV A day, this stock will fly finally. For the moment, investors have not fully understood where they are sitted. Opposite they was not just daily trading. Strange but true story of this stock. Till people will not stop to sell on the base of nothyng, the stock will never go up seriously. And we need the price at a certain level where stock will start after a catalyst. In all cases, RA capital is still in and they are in waiting mode. And someone is loading, and loading and smiling every time price going down. We will see. I stay long and focused to the company success. All daily trader better they stay out. To gain a beer and a pizza maybe better to go in other stock.
1 · Reply
Dani_G_German
Dani_G_German Aug. 24 at 7:18 PM
$ACRV 👀
0 · Reply